Current
6.1×
5-Year Average
93.7×
All-Time High
278.5×
All-Time Low
3.7×
P/B Ratio daily chart for Novo Nordisk (NVO)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/B Ratio for Novo Nordisk (NVO) from 2004 to 2025
| 2025 | $226.31B | $30.52B | 7.4× | -11.8× | |
| 2024 | $383.10B | $19.92B | 19.2× | -9.7× | |
| 2023 | $455.77B | $15.78B | 28.9× | +3.5× | |
| 2022 | $305.06B | $12.02B | 25.4× | +1.7× | |
| 2021 | $256.12B | $10.82B | 23.7× | -71.2× | |
| 2020 | $162.15B | $1.71B | 94.9× | -10.4× | |
| 2019 | $136.69B | $1.30B | 105.3× | +91.3× | |
| 2018 | $111.37B | $7.96B | 14.0× | -2.7× | |
| 2017 | $133.70B | $8.03B | 16.7× | +2.6× | |
| 2016 | $90.10B | $6.41B | 14.1× | -7.7× | |
| 2015 | $149.17B | $6.84B | 21.8× | +4.9× | |
| 2014 | $110.79B | $6.55B | 16.9× | +4.4× | |
| 2013 | $98.35B | $7.87B | 12.5× | +0.1× | |
| 2012 | $89.07B | $7.19B | 12.4× | +2.4× | |
| 2011 | $65.08B | $6.53B | 10.0× | +0.2× | |
| 2010 | $64.87B | $6.64B | 9.8× | +4.3× | |
| 2009 | $37.92B | $6.88B | 5.5× | +0.4× | |
| 2008 | $31.66B | $6.21B | 5.1× | -1.4× | |
| 2007 | $40.98B | $6.31B | 6.5× | +1.5× | |
| 2006 | $26.80B | $5.33B | 5.0× | +0.8× | |
| 2005 | $18.37B | $4.38B | 4.2× | +0.5× | |
| 2004 | $18.19B | $4.87B | 3.7× | — |
- 20257.4×
- 202419.2×
- 202328.9×
- 202225.4×
- 202123.7×
- 202094.9×
- 2019105.3×
- 201814.0×
- 201716.7×
- 201614.1×
- 201521.8×
- 201416.9×
- 201312.5×
- 201212.4×
- 201110.0×
- 20109.8×
- 20095.5×
- 20085.1×
- 20076.5×
- 20065.0×
- 20054.2×
- 20043.7×
About P/B Ratio at Novo Nordisk (NVO)
Novo Nordisk (NVO) P/B ratio is 6.1× as of June 5, 2026. The 5-year average is 93.7×. The sector median currently stands at 3.4×. The current ratio is at the 4th percentile of its own 10-year history.
Novo Nordisk (NVO) historical P/B ratio has ranged from a low of 3.7× (2004) to a high of 278.5× (2024) in the available daily series.
The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.
Novo Nordisk P/B Ratio by Year
Novo Nordisk P/B Ratio 2025: 7.4×
Novo Nordisk (NVO) P/B ratio in 2025 was 7.4×, contracted from 19.2× the prior year.
Novo Nordisk P/B Ratio 2024: 19.2×
Novo Nordisk (NVO) P/B ratio in 2024 was 19.2×, contracted from 28.9× the prior year.
Novo Nordisk P/B Ratio 2023: 28.9×
Novo Nordisk (NVO) P/B ratio in 2023 was 28.9×, expanded from 25.4× the prior year.
Novo Nordisk P/B Ratio 2022: 25.4×
Novo Nordisk (NVO) P/B ratio in 2022 was 25.4×, expanded from 23.7× the prior year.
Novo Nordisk P/B Ratio 2021: 23.7×
Novo Nordisk (NVO) P/B ratio in 2021 was 23.7×.
Sector peers by P/B Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/B Ratio — table
Healthcare peers of Novo Nordisk (NVO), ranked by P/B ratio.
| 2.9× | |
| 2.7× | |
| 2.6× | |
| 2.6× | |
| 2.5× | |
| 2.5× | |
| 2.4× | |
| 2.4× | |
| 2.3× | |
| 1.8× | |
| 1.8× | |
| 1.7× | |
| 1.7× | |
| 1.6× | |
| 1.5× | |
| 1.5× | |
| 1.5× | |
| 1.4× | |
| 1.4× | |
| 1.4× | |
| 1.2× | |
| 1.2× | |
| 1.1× | |
| 1.1× | |
| 0.8× |
- 2.7×
- 2.4×
- 2.3×
- 1.8×
- 1.7×
- 1.4×
- 1.4×
- 1.2×
- 1.1×
- 1.1×
- 0.8×
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric